Testing Lower Tocilizumab Dosing in Adults With Rheumatoid Arthritis
Compares standard tocilizumab dosing with less frequent dosing in adults with rheumatoid arthritis.
Key facts
- Who runs it
- Reade revalidatie & reumatologie centrum te Amsterdam
- Where
- Alkmaar, Amsterdam, Rotterdam, and Ubbergen, NetherlandsSee the 6 sites
- Registry title
- Tocilizumab Dose Optimization in Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 98 people, planned
- Started
- 20 Jan 2025
- Planned end
- 1 Oct 2025
- Type of study
- Interventional
- Record updated
- 16 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis who have used weekly tocilizumab injections for at least 6 months. It tests whether the dose can be given less often.
- Age
- 18 years and older
- Sex
- Men and women can join.
- Disease stage
- Rheumatoid arthritis confirmed by the ACR 1987 or 2010 criteria. The treating rheumatologist is convinced tocilizumab should continue.
- Earlier treatment
- Must currently use subcutaneous tocilizumab 162 mg weekly, for at least the last 6 months. No changes in glucocorticoid or DMARD treatment (such as methotrexate) in the past three months.
Main reasons for not taking part
- Surgery scheduled in the next 52 weeks
- Other pre-planned reasons to stop treatment
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Rheumatoid arthritis according to the ACR 1987 or 2010 criteria
- Current use of subcutaneous tocilizumab 162 mg weekly , for at least the last 6 months
- The treating rheumatologist is convinced of the benefit of tocilizumab continuation
- No changes in the treatment with glucocorticoids and DMARDs such as methotrexate in the past three months
- Written informed consent
Who cannot take part
- A scheduled surgery in the next 52 weeks or other pre-planned reasons for treatment discontinuation
Where in Netherlands
- Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Reade revalidatie & reumatologie centrum te AmsterdamAmsterdam, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
- Sint Maartenskliniek StichtingUbbergen, NetherlandsTaking people
About the trial
What the trial wants to find out
The main objective is to investigate the difference in mean time weighted Disease Activity Score in 28 joints, including erythrocyte sedimentation rate (DAS28-ESR) in patients with RA with serum trough concentrations higher than 15 mg/L who are randomly assigned to continuation of the standard dose or to increase dosing interval to every two weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Concentration guided dose reduction versus standard dosing in tocilizumab treated heumatoid arthritis patients:a randomised, international, multicenter, non-inferiority trial
- Plain-language title
- Testing Lower Tocilizumab Dosing in Adults With Rheumatoid ArthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 January 2025